Climb Bio, Inc.

NASDAQ•CLYM

CEO: Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-08-10

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Contact Information

PMB #117, 2801 Centerville Road, 1st Floor, Wilmington, DE, 19808-1609, United States

866-857-2596

eliemtx.com

Market Cap

$499.79M

P/E (TTM)

-8.3

17.5

Dividend Yield

52W High

$8.03

52W Low

$1.05

52W Range

90%

Rank49Top 66.7%

3.2

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 3.2 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.26+0.00%

4-Quarter Trend

FCF

-$15.64M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Loss Narrows Net loss narrowed to $(59.851M) USD in 2025 from $(73.897M) USD in 2024, showing operational improvement.

R&D Investment Surge Research and development expenses rose $32.377M to $46.713M USD, driven by advancement of budoprutug programs.

Strong Liquidity Position Cash and marketable securities totaled $160.744M USD as of December 31, 2025, funding operations into 2028.

Risk Factors

Future Capital Needs Expect continued operating losses; substantial future financing required to fund development and potential commercialization efforts.

Development Uncertainty Clinical development is lengthy, complex, and expensive; success is not guaranteed for product candidates like budoprutug.

Internal Control Weaknesses Material weaknesses in internal control over financial reporting remain unremediated as of December 31, 2025, impacting timely reporting.

Outlook

Budoprutug pMN Data Expected Anticipate reporting initial data from the low dose cohort of the PrisMN Phase 2 trial in the second half of 2026.

SC Formulation Data Coming Plan to share initial data from the Phase 1 clinical trial of the subcutaneous formulation in the first half of 2026.

CLYM116 Phase 1 Results Expect initial data from the CLYM116 Phase 1 trial in mid-2026 to support advancement into IgA Nephropathy patients.

Peer Comparison

Revenue (TTM)

AGEN

$106.83M

-33.4%

SPRO

$35.77M

-64.7%

SEER

$16.58M

+18.2%

Gross Margin (Latest Quarter)

SPRO

100.0%

+0.0pp

OVID

87.1%

-12.9pp

SEER

52.0%

+4.3pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CLYM	$499.79M	-8.3	-33.4%	0.3%
CNTX	$268.29M	-10.5	-30.9%	0.2%
ABOS	$203.53M	-1.5	-97.4%	21.7%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Mar 24, 2026

EPS:-$0.20

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data